Natalizumab is a monoclonal antibody directed against the α4 chain of the very late activating antigen 4 and α4β7 integrins, present on the leukocytes surface, used as monotherapy for the treatment of relapsing-remitting multiple sclerosis. It substantially reduces relapse rate and the accumulation of disability, but its use is associated with a very adverse event, that is the development of progressive multifocal leukoencephalopathy, a fatal demyelinating disease of the CNS, due to the lytic replication of the human polyomavirus JC. The main focus of the review is to describe the newest insights on natalizumab, its current use in the clinical practice, the natalizumab-treated patients' management and the risk stratification related to the progressive multifocal leukoencephalopathy development.

Natalizumab treatment of multiple sclerosis: new insights / S. Delbue, M. Comar, P. Ferrante. - In: IMMUNOTHERAPY. - ISSN 1750-743X. - 9:2(2017), pp. 157-171.

Natalizumab treatment of multiple sclerosis: new insights

S. Delbue
;
P. Ferrante
Ultimo
2017

Abstract

Natalizumab is a monoclonal antibody directed against the α4 chain of the very late activating antigen 4 and α4β7 integrins, present on the leukocytes surface, used as monotherapy for the treatment of relapsing-remitting multiple sclerosis. It substantially reduces relapse rate and the accumulation of disability, but its use is associated with a very adverse event, that is the development of progressive multifocal leukoencephalopathy, a fatal demyelinating disease of the CNS, due to the lytic replication of the human polyomavirus JC. The main focus of the review is to describe the newest insights on natalizumab, its current use in the clinical practice, the natalizumab-treated patients' management and the risk stratification related to the progressive multifocal leukoencephalopathy development.
No
English
disease modifying therapy; multiple sclerosis; natalizumab; progressive multifocal leukoencephalopathy; Immunology and Allergy; Immunology; Oncology
Settore MED/07 - Microbiologia e Microbiologia Clinica
Review essay
Esperti anonimi
Pubblicazione scientifica
2017
Future Medicine Ltd.
9
2
157
171
15
Pubblicato
Periodico con rilevanza internazionale
http://www.futuremedicine.com/loi/imt
scopus
pubmed
crossref
Aderisco
info:eu-repo/semantics/article
Natalizumab treatment of multiple sclerosis: new insights / S. Delbue, M. Comar, P. Ferrante. - In: IMMUNOTHERAPY. - ISSN 1750-743X. - 9:2(2017), pp. 157-171.
none
Prodotti della ricerca::01 - Articolo su periodico
3
262
Article (author)
si
S. Delbue, M. Comar, P. Ferrante
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/501053
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 12
social impact